1/5/2010 10:01:43 AM
SAN ANTONIO--(BUSINESS WIRE)--Dr. Anthony Tolcher, clinical director for South Texas Accelerated Research Therapeutics (START) at the START Center for Cancer Care in San Antonio, announced today that the first patient has been enrolled in a groundbreaking Phase I clinical trial of a novel combination anticancer regimen composed of two investigational compounds: MK-2206 from Merck & Co., Inc. (NYSE:MRK) and AZD6244 (ARRY-886*) from AstraZeneca (NYSE:AZN). In June of this year, AstraZeneca and Merck made national news when they announced what they called “a pioneering collaboration” to research a novel combination anticancer regimen composed of two investigational compounds, saying that this is the first time that two large pharmaceutical companies have joined together to evaluate the potential for combining candidate molecules at such an early stage of development. START has been chosen as the first Phase I center to test the drug combination. START conducts the world’s largest Phase I clinical trials program for oncology.
comments powered by